drugset / Trial / NCT06522373
Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To learn if MT-0169 is safe to give to patients with AML or T-ALL. The effects of this drug will also be studied.
Timeline
- Start
- 2024-10-21
- Primary completion
- 2024-10-21
- Completion
- 2024-10-21
Outcome
Outcome not reported
Stopped: “PI Request”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MT-0169 | Protein / enzyme biologic | — | Intravenous |